What are the payment terms accepted?

Accepted payment terms include LC, T/T, and D/P.

What is the average lead time for orders?

The average lead time is 1-3 months for both peak and off-peak seasons.

What is the main market for this product?

Main markets include South America, Southeast Asia/Mideast, and Africa.

Furosemide Injection with GMP From Reyoung Pharma in China

Name: Furosemide Injection with GMP From Reyoung Pharma in China
Brand: REYOUNG PHARMACEUTICAL CO., LTD.
SKU: 758845042

Shandong, ChinaREYOUNG PHARMACEUTICAL CO., LTD.

US$0.12

600,000 ampoules

Product profile

Customization

Available

Application

Internal Medicine

Usage Mode

Intravenous Injection

Model NO.

2ml: 20mg

Suitable for

Elderly, Children, Adult

State

Liquid

Shape

Injection

Type

Inorganic Chemicals

Pharmaceutical Technology

Chemical Synthesis

Standard

USP

Packaging

10AMPS/Tray,10tray/Box

Transport Package

Carton

Specification

Furosemide

Trademark

Reyoung

Origin

No.1 Ruiyang Road,Yiyuan County, Shandong Province

Key features

Rapid Diuretic Effect: Provides powerful and fast diuretic action to reduce heart preload and alleviate heart failure symptoms.

Suitable for Elderly: Specifically indicated for elderly patients with first or second grade hypertension and concurrent heart failure.

GMP Certified Manufacturing: Produced by Reyoung Pharma with GMP standards, ensuring high quality and safety for pharmaceutical use.

OEM and ODM Services: Manufacturer offers both OEM and ODM services to meet custom branding and formulation needs.

Standard USP Compliance: Product specifications adhere to USP standards for purity and efficacy in chemical synthesis.

Versatile Patient Groups: Suitable for use in elderly, children, and adult populations for treating various edema and hypertension conditions.

Comprehensive Product Range: Manufacturer specializes in powders, injections, tablets, capsules, and sterile raw materials.

Global Export Capability: Established export presence since 1997 with major markets in South America, Southeast Asia, and Africa.

Company profile

REYOUNG PHARMACEUTICAL CO., LTD.

Shandong, China

CertifiedBusiness Type: Manufacturer/Factory & Trading Company CertifiedR&D Capacity: ODM Service Available & OEM Service AvailableExport Year: 1997-01-01 CertifiedNearest Port: Qingdao PortAverage Response Time: ≤24h CertifiedTerms of Payment: LC, T/T, D/P

AI-Powered supplier vetting

SummaryREYOUNG PHARMACEUTICAL CO., LTD. is a China-based limited company established in 1998, with 4,950 employees and operations in Shandong. The supplier reports ISO 9001, ISO 14001, and OHSAS 18001 certifications, more than 10 production lines, 50 quality-control staff, and 370 years of combined R&D-engineer experience. Its stated manufacturing portfolio includes sterile raw materials, powders and liquids for injection, tablets, and capsules, with reported annual production above the stated threshold. The company identifies three factories, an extensive manufacturing area, international business since 1997, and export markets across South America, Africa, Southeast Asia, and the Middle East. Trade records show transactions involving India, Bolivia, and Vietnam, including cefotaxime-related products. Evidence is insufficient to assess after-sales service, financial credibility, innovation output, or customization capability. Customer-case evidence is limited to named buyers and trade records.

Supplier typeThe supplier is identified as a combined business entity and a limited company headquartered in Shandong, China. Its business scope is health and medicine, with products including sterile raw materials, injectable products, tablets, and capsules, supporting classification as a pharmaceutical manufacturer and distributor.

CertificationsThe supplier explicitly reports ISO 9001:2015, ISO 14001:2015, and OHSAS 18001:2007 certificates, and separately describes itself as GMP and ISO authenticated. These stated certifications provide direct evidence of formal quality, environmental, and occupational-health management systems.

Production capacityProduction capacity is supported by more than 10 production lines, three factories, a reported manufacturing area of 1,000,000 square meters, and stated annual output across small-volume injections, powder injections, tablets, and capsules. The supplier also reports annual production above the stated threshold, indicating substantial multi-form pharmaceutical manufacturing capability.

Client casesTrade records identify transactions involving STERILE INDIA PRIVATE LIMITED, HEREDIA ARACENA RENY EVELIN, and a Vietnam-related registration, with products including cefotaxime-related material and oral rehydration products. These records demonstrate some international commercial activity, but the evidence is limited and does not establish long-term customer performance or a broad verified customer portfolio.

Product Q&A

Q:What is the primary indication for Furosemide Injection?

It is suitable for treating first or second grade hypertension, especially in the elderly, and is used for heart, kidney edema, cirrhosis ascites, and heart failure.

Q:What is the dosage specification?

The standard specification is 2ml containing 20mg of Furosemide.

Q:How should electrolyte levels be managed during use?

Electrolyte levels should be regularly monitored during use to avoid side effects caused by electrolyte disturbance.

Q:What are the available packaging options?

Packaging is available as 10 amps per tray, with 10 trays per box.

Q:Does the manufacturer offer OEM or ODM services?

Yes, the manufacturer offers both OEM and ODM services.